Answers are grounded in this paper and cite their sources.
This study analysed 135 plasma samples from 56 NSCLC patients treated with curative intent chemoradiotherapy using a tumor-agnostic approach. Detecting ctDNA at 4.5 months post-treatment was linked to higher recurrence odds, indicating ctDNA's potential as a biomarker for identifying residual disease after treatment with curative intent. Importantly, the study emphasizes the importance of timing for accurate ctDNA analysis results.
No takes yet. Share an insight, caveat, or question.
Nielsen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: